New Drug Approvals Archive - July 2012
Get news by email or subscribe to our news feeds.
July 2012
Truvada (emtricitabine and tenofovir)
New Indication Approved: July 16, 2012
Read more: Truvada (emtricitabine and tenofovir) FDA Approval History
Prepopik (sodium picosulfate, magnesium oxide and citric acid) for Oral Solution
Date of Approval: July 16, 2012
Company: Ferring Pharmaceuticals
Treatment for: Bowel Preparation
Prepopik (sodium picosulfate, magnesium oxide and citric acid) is a stimulant laxative and osmotic laxative combination indicated for cleansing of the colon as a preparation for colonoscopy in adults.
Read more: Prepopik (sodium picosulfate, magnesium oxide and citric acid) FDA Approval History
Qsymia (phentermine and topiramate) Extended-Release Capsules - formerly Qnexa
Date of Approval: July 17, 2012
Company: Vivus, Inc.
Treatment for: Obesity
Qsymia (phentermine and topiramate) is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate extended-release, an antiepileptic drug, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.
Read more: Qsymia (phentermine and topiramate) FDA Approval History
Kyprolis (carfilzomib) Injection
Date of Approval: July 20, 2012
Company: Amgen Inc.
Treatment for: Multiple Myeloma
Kyprolis (carfilzomib) is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma.
Read more: Kyprolis (carfilzomib) FDA Approval History
Afinitor (everolimus)
New Indication Approved: July 20, 2012
Read more: Afinitor (everolimus) FDA Approval History
Tudorza (aclidinium bromide) Pressair
Date of Approval: July 23, 2012
Company: Allergan, Inc.
Treatment for: Chronic Obstructive Pulmonary Disease
Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Read more: Tudorza (aclidinium bromide) FDA Approval History
Vascepa (icosapent ethyl) Capsules
Date of Approval: July 26, 2012
Company: Amarin Corporation plc
Treatment for: Hypertriglyceridemia
Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia.
Rayos (prednisone) Delayed-Release Tablets - formerly Lodotra
Date of Approval: July 26, 2012
Company: Horizon Pharma, Inc.
Treatment for: Rheumatoid Arthritis, Polymyalgia Rheumatica, Psoriatic Arthritis, Ankylosing Spondylitis, Asthma, Chronic Obstructive Pulmonary Disease
Rayos (prednisone) is a delayed release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases including rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease (COPD).
Read more: Rayos (prednisone) FDA Approval History
Kyprolis (carfilzomib)
New Indication Approved: July 24, 2015
Read more: Kyprolis (carfilzomib) FDA Approval History
Kyprolis (carfilzomib)
New Indication Approved: January 21, 2016
Read more: Kyprolis (carfilzomib) FDA Approval History